AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure-Reference-Cited by-同舟云学术

AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure

Published:2018-03-16 Issue:3 Volume:365 Page:567-572
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Pehrson Rikard,Hegelund-Myrbäck Tove,Cunoosamy Danen,Asimus Sara,Jansson Paul,Patel Naimish,Borde Annika,Lundin Sofia

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference26 articles.

1. Brough S, Evans R, Luker TJ, and Raubo P (2008) inventors, Astrazeneca Ab, assignee. Pyrazinone derivates and their use in the treatment of lung diseases. U.S. Patent WO 2,009,001,132. 2008 Dec 31.

2. SD0006: A Potent, Selective and Orally Available Inhibitor of p38 Kinase

3. p38 Mitogen-Activated Protein Kinase Pathways in Asthma and COPD

4. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

5. Optimisation of DMPK by the Inhaled Route: Challenges and Approaches

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder;Frontiers in Pharmacology;2024-03-14

2. Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective;Drug Discovery Today;2022-01

3. Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19;Pharmacology & Therapeutics;2021-05

4. The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors;Bioorganic & Medicinal Chemistry Letters;2020-09